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Glutamate dehydrogenase (GDH, E.C. 1.4.1.3.) is a key enzyme for the biosynthesis and modulation of glutamate (GLU)
metabolism and an indirect γ-aminobutyric acid (GABA) source, here we studied the eﬀect of anticonvulsants such as pyridoxal
phosphate (PPAL), aminooxyacetic acid (AAOA), and hydroxylamine (OHAMINE) on GDH activity in mouse brain. Moreover,
since GLU is a glucogenic molecule and anoxia is a primary cause of convulsions, we explore the eﬀect of these drugs on oxygen
consumption. Experiments were performed in vitro as well as in vivo for both oxidative deamination of GLU and reductive
amination of α-ketoglutarate (αK). Results in vitro showed that PPAL decreased oxidative deamination of GLU and oxygen
consumption,whereasAAOAandOHAMINEinhibitedGDHactivitycompetitivelyandalsoinhibitedoxygenconsumptionwhen
αK reductive amination was carried out. In contrast, results showed that in vivo, all anticonvulsants enhanced GLU utilization
by GDH and also decreased oxygen consumption. Together, results suggest that GDH activity has repercussions on oxygen
consumption, which may indicate that the enzyme activity is highly regulated by energy requirements for metabolic activity.
Besides, GDH may participate in regulation of GLU and, indirectly GABA levels, hence in neuronal excitability, becoming a key
enzyme in seizures mechanism.
1.Introduction
Seizures are considered to be the result of an unbalance
between excitatory and inhibitory systems, and it is believed
that anticonvulsants exert their actions through enhance-
ment of inhibitory-mediated transmission, the reduction of
excitatory-mediated transmission, or a combination of both
[1].
Glutamate (GLU) is considered the main excitatory neu-
rotransmitter in the central nervous system (SNC) in
mammals, besides, it is the precursor for the biosynthesis
of gamma-aminobutyric acid (GABA), the main inhibitory
neurotransmitter. It has been proposed that GLU may be
involved in the pathogenesis of seizures [2], since many
pathological processes in the SNC leading to the develop-
ment of convulsive syndrome can increase the activity of
glutamatergic transmission as the common end pathway [3–
7].
Glutamate dehydrogenase (GDH, EC 1.4.1.3.) catalyzes
the reversible deamination of L-glutamate to 2-oxoglutarate.
Evidences of the particular importance of GDH activity
in the nervous system are GDH isolated from patients
with heterogeneous neurological disorders, characterized by
multisystem atrophy, displayed a marked reduction on its
activity [8], with a similar trend in cortex and hippocampus
ofpatientswithtemporallobeepilepsy[9].Increasedactivity
of GDH has been reported in epileptic focus of human brain
[10]. In addition, it has been proposed that pathogenesis of
epilepsy in patients with hyperinsulinism/hyperammonemia
syndrome may be related to an increasing GDH activity [11].
On the other hand, hypoxia is considered as a primary
cause of seizures. Although this eﬀect could be mediated2 ISRN Pharmacology
by free radicals [12–15], many studies have shown that
following hypoxic and ischemic injury in the brain, there
is an excessive release of GLU and overstimulation of its
receptors [16–18]. GDH might participate in this eﬀect
generating GLU, but also as a source of energy for the
oxidative metabolism in the brain through the Krebs cycle.
The management of seizures in epileptic patients relies
heavily on anticonvulsant drugs therapy. In an eﬀort to
elucidate the possible correlation between GDH and oxygen
consumption and its possible participation in seizures mech-
anism here we report the eﬀect of diﬀerent anticonvulsant
drugs on GDH activity and oxygen consumption in vitro as
well as in vivo, studying oxidative deamination of GLU and
reductive amination of α-ketoglutarate (αK).
2.MaterialandMethods
2.1. Animals. Experiments were conducted in accordance
with Helsinki Guide for the Care and Use of Laboratory
Animals as adopted and promulgated by de EU Directive
2010/63/EU for animal experiments and approved by the
institutional committee of ethics of E.N.C.B.
Albino male mice with a mean weight of 25g, fed ad
libitum on a stock laboratory diet (49.8% carbohydrates,
23.5% protein, 3.7% fat, minerals and added vitamins and
amino acids; w/w), were used for the experiments. The
animals were maintained on a 12 h light-dark cycle.
2.2. Reagents. Pyridoxal phosphate (PPAL) aminooxyacetic
acid (AAOA), and GDH were purchased from Sigma Chem-
ical co. (USA); Hydroxylamine (OHAMINE) was obtained
from Merck (Dramstad, Germany). All anticonvulsants were
dissolved in phosphate buﬀer (pH = 7.4).
Standard analytical grade laboratory reagents were
obtained from Merck or Sigma-Aldrich Chemical Corpora-
tion.
2.3. GDH Activity Determination
2.3.1. Tissue Processing. Animals without treatment (for in
vitro assays) or after the treatment (for in vivo assays), were
sacriﬁced and whole wet brains were removed. 25% (wt/vol)
homogenates was prepared with a Glas-Col tissue homog-
enizer in a 5% Triton X-100 solution. After centrifugation
(12,500 RPM/45min.), GDH activity was determined in the
supernatant using a spectrophotometric assay according to
the Strecker method [19]. Enzymatic activity assays were
performed for the GLU oxidative deamination (forward
reaction) and reductive amination of αK (backward reac-
tion).
2.3.2. Oxidative Deamination of Glutamate. Reaction medi-
um was composed of phosphate buﬀer 0.05M pH = 7.6,
NAD (0.036M) and brains supernatant (see Section 2.3.1.).
Reaction started by adding GLU (0.5M pH = 7.0).
2.3.3. Reductive Amination of α-Ketoglutarate. Reaction me-
dium was composed of phosphate buﬀer 0.05M pH = 7.6,
NADH (0.0113M), NH4SO4 (0.3M), and brain super-
natants (see Section 2.3.1.). Reaction started by addition of
α-ketoglutarate (0.04M pH = 6.8).
2.4. Eﬀect of Anticonvulsant Drugs on Brain GDH Activity
2.4.1. In Vitro Eﬀect of Anticonvulsant Drugs on Brain
GDH Activity. Diﬀerent concentrations of PPAL, AAOA,
and OHAMINE (between 0.001 and 0.00001M) were added
to the supernatant obtained from brain homogenates of
animals.GDHactivitywasdetermined10,20,30,and60min
after reaction was initiated.
2.4.2. Eﬀect of Aminooxyacetic Acid and Hydroxylamine on
GDH of Diﬀerent Sources. Eﬀect of diﬀerent concentrations
of AAOA and OHAMINE (0.001, 0.0001, and 0.00001M)
on GDH activity of mouse brain, mouse liver (processed
exactly as described for brains in Section 2.4.1.), and com-
mercially available (from bovine liver, glycerol solution and
ammonium-free diluted in phosphate buﬀer 0.05M pH 7.6).
2.4.3. Eﬀect of Diﬀerent Concentrations of Ammonium on
GDH Activity with and without Aminooxyacetic Acid and
Hydroxylamine. GDH activity was determined using dif-
ferent concentrations of ammonium (between 40μMa n d
200μM) with and without AAOA and OHAMINE 0.001 and
0.0001M.
2.4.4. In Vivo Eﬀect of Anticonvulsant Drugs on Brain GDH
Activity. PPAL (50mg/kg 30, 60 and 120min) OHAMINE
(40mg/kg 1, 2, and 4 hours), AAOA (40mg/kg 30, 60
and 120min), and HEPB (30, 60, and 120min) were
administrated (IP) to groups of 5 animals at the dosage
and during the time indicated. Animals were sacriﬁced and
brains were quickly removed and processed for GDH activity
determination as described in Section 2.3.
2.5. Oxygen Consumption
2.5.1. Tissue Processing. Animals were sacriﬁced, and once
brains were excised, a 25% (wt/vol) homogenates in sucrose
0.25M was prepared. Homogenates were centrifuged at
3500rpm for 10 minutes, and supernatants were used to
determine oxygen consumption by a polarographic method
using a biological oxygen monitor YSI 5300. Determinations
were performed using the same medium of reaction used for
determination of oxidative deamination of GLU and reduc-
tive amination of αK catalyzed by GDH (see Sections 2.3.2.
and 2.3.3.).
2.5.2. In Vitro Eﬀect of Anticonvulsant Drugs on Brain GDH
Activity. To the supernatant obtained from animals without
treatment as described above were added concentrations
of 0.001, 0.0001, and 0.00001M of PPAL, AAOA, and
OHAMINE and oxygen consumption was measured.ISRN Pharmacology 3
PPAL
Time (minutes)
0 10 20 30 40 50 60
G
D
H
 
a
c
t
i
v
i
t
y
/
m
g
 
o
f
 
p
r
o
t
e
i
n
 
(
%
)
0
20
40
60
80
100
Control
aa
b
c c c
d
e e e
f
g g g
 aa a
h h h h
1×10−5 M
5×10−5 M
1×10−4 M
1×10−3 M
(a)
AAOA
Time (minutes)
0 10 20 30 40 50 60
G
D
H
 
a
c
t
i
v
i
t
y
/
m
g
 
o
f
 
p
r
o
t
e
i
n
 
(
%
)
0
20
40
60
80
100 a a a a
b b b
b
c
d e e
f f f
f
a
Control
1×10−5 M
1×10−4 M
1×10−3 M
(b)
OHAMINE
Time (minutes)
0
0
10 20 30 40 50 60
G
D
H
 
a
c
t
i
v
i
t
y
/
m
g
 
o
f
 
p
r
o
t
e
i
n
 
(
%
)
20
40
60
80
100
aaaa a
a aaa a
b
c d
Control
1×10−5 M
1×10−4 M
1×10−3 M
(c)
Figure 1: Eﬀect in vitro of some anticonvulsant drugs on glutamate oxidative deamination catalized by mouse brain glutamate dehydro-
genase. Glutamate dehydrogenase activity (GDH) was determined in mouse brain homogenates (1:5 w:v on phosphates 0.05M pH = 7.6
buﬀer) with diﬀerent concentrations of pyridoxal phosphate (PPAL), hydroxylamine (OHAMINE) and aminooxyacetic acid (AAOA) with
glutamic acid as substrate, using a spectrophotometric method (see Section 2). Results are means ± SEM (n>4). ANOVA test was applied
and diﬀerent characters were used to indicate statistically diﬀerent groups as compared with the control (P>0.01, Tuckey’s test).
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Figure 2: Eﬀect in vitro of some anticonvulsant drugs on reductive amination of α-ketoglutarate catalaized by mouse brain glutamate
dehydrogenase. Glutamate dehydrogenase activity (GDH) was determined in mouse brain homogenates (1:5 w:v on phosphates 0.05M
pH = 7.6 buﬀer) with diﬀerent concentrations of pyridoxal phosphate (PPAL), hydroxylamine (OHAMINE), and aminooxyacetic acid
(AAOA) with α-ketoglutarate as substrate, using a spectrophotometric method (see Section 2). Results are means ± SEM (n>4). ANOVA
test was applied and diﬀerent characters were used to indicate statistically diﬀerent groups as compared with the control (P>0.01, Tuckey’s
test).4 ISRN Pharmacology
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Figure 3: Eﬀect in vitro of aminooxiacetic and hydroxylamine on glutamate dehydrogenase activity of diﬀerent sources. Eﬀect of diﬀerent
concentrations of aminooxyacetic acid (AAOA), and hydroxylamine (OHAMINE) on reductive amination of α-ketoglutarate and oxidative
deamination of glutamate respectively, catalyzed by glutamate dehydrogenase commercially available (from bovine liver), mouse brain,
and liver homogenates (1:5 w:v on phosphates 0.05M pH = 7.6 buﬀer), using a spectrophotometric method (see Section 2). Results are
means ± SEM (n>4). ANOVA test was applied, and diﬀerent characters were used to indicate statistically diﬀerent groups as compared with
the control (P>0.01, Tuckey’s test).
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Figure 4: Eﬀect of ammonium sulphate on the inhibitory activity of aminooxyacetic acid and hydroxylamine on mouse brain glutamate
dehydrogenase. Glutamate dehydrogenase activity (GDH) was determined in mouse brain homogenates (1:5 w:v on phosphates 0.05M
pH = 7.6 buﬀer) for reductive amination of α-ketoglutarate employing diﬀerent concentrations of ammonium sulphate, with and without
aminooxyacetic acid (AAOA, (a)) and hydroxylamine (OHAMINE, (b)), using a spectrophotometric method (see Section 2). Reciprocal of
GDH activity are plotted against reciprocal of ammonium concentration.ISRN Pharmacology 5
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Figure 5: Eﬀect in vivo of some anticonvulsant drugs on mouse brain glutamate dehydrogenase. Animals received pyridoxal phosphate
(PPAL, 50mg/Kg), hydroxylamine (OHAMINE, 40mg/kg), and aminooxyacetic acid (AAOA, 40mg/Kg). After diﬀerent times of treatment,
glutamate dehydrogenase activity (GDH) was determined in brain homogenates (1:5 w:v on phosphates 0.05M pH = 7.6 buﬀer) for
oxidative deamination of glutamate and reductive amination of α-ketoglutarate, using a spectrophotometric method (see Section 2). Results
are means ± SEM (n>4). ANOVA test was applied and diﬀerent characters were used to indicate statistically diﬀerent groups as compared
with the control (P>0.01, Tuckey’s test).
2.5.3. In Vivo Eﬀect of Anticonvulsant Drugs on Brain GDH
Activity. Groups of ﬁve animals received PPAL (50mg/kg),
AAOA (40mg/kg) and OHAMINE (40mg/kg) IP and after
1 hour, animals were sacriﬁced and brains were quickly
removed and once processed oxygen consumption determi-
nation was performed.
2.6. Protein Levels. Protein concentration was determined in
supernatants by Lowry method [20].
2.7. Statistical Analyses. All results that were normalized
against control were in turn mean ± SE values of at least
four determinations (n ≥ 4). GDH activity was compared
between groups by using one-way analysis of variance
(ANOVA), followed by Tukey’s multiple comparisons. A P
value of 0.01 was regarded as statistically signiﬁcant.
3. Results
3.1. Anticonvulsant Drugs and Brain GDH Activity In Vitro.
Figures 1 and 2 represent the eﬀect of anticonvulsants on
GDH activity in vitro. Results show that PPAL decreased
GLU oxidative deamination in a concentration dependent
manner, it was totally inhibited at 0.001M.
AAOA and OHAMINE decreased GDH activity using
GLU as substrate 30 and 18%, respectively. Although this
inhibition is signiﬁcant, the eﬀect produced by these sub-
stances is higher in reductive amination of αK, reaching 90
and70%ofinhibition,respectively.PPALinhibitedreductive
amination of αK, but only 25% as maximum.
3.2. Eﬀect of Aminooxyacetic Acid and Hydroxylamine on
GDH of Diﬀerent Sources . Ac o m p a r i s o no fe ﬀects of AAOA
and OHAMINE on GDH from diﬀerent sources is shown
in Figure 3, where can be appreciated that whereas mouse
liver and commercial GDH inhibited only slightly reductive
amination of αK, mouse brain GDH activity is decreased
about 70%.
3.3. Eﬀect of Ammonium on GDH Activity with and without
Aminooxyacetic Acid and Hydroxylamine. Lineweaver-Burk
graph for AAOA and OHAMINE eﬀects on GDH activity,
using ammonium as substrate, can be observed in Figure 4.
ResultsindicateacompetitiveinhibitionofbrainGDHactiv-
ityforbothanticonvulsants,withaKmvalueof20.8μM,and
71.43μM, respectively.
3.4. Anticonvulsant Drugs and GDH Activity In Vivo . The
eﬀect of administration of anticonvulsant drugs on brain
GDH activity was also investigated. In vivo results are
diﬀerent to the observed in vitro, since an increase in GLU
oxidative deamination catalyzed by GDH was found in all
cases (Figure 5(a)). Anticonvulsant drugs caused also an
increase on α ketoglutaric reductive amination (except for
AAOA, Figure 5(b)), but this eﬀect was of smaller magnitude
compared with the observed for GLU utilization.6 ISRN Pharmacology
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Figure 6: Eﬀect in vitro of some anticonvuulsant drugs on oxygen consumption. Diﬀerent concentrations of pyridoxal phosphate (PPAL),
hydroxylamine (OHAMINE), and aminooxyacetic acid (AAOA) were added and oxygen consumption was determined in mouse brain
homogenates (25% wt/vol in sucrose 0.25M) by a polarographic method using glutamate (a) and α-ketoglutarate (b) as substrates (see
Section 2). Results are means ± SEM (n>4). ANOVA test was applied and diﬀerent characters were used to indicate statistically diﬀerent
groups as compared with the control (P>0.01, Tuckey’s test).
3.5. Anticonvulsant Drugs and Oxygen Consumption In Vitro.
As observed in GDH activity, in vitro eﬀects of anticon-
vulsant drugs on oxygen consumption depend on type
of substrate. Results (Figure 6) show that PPAL decreased
oxygen consumption when GLU was the substrate. AAOA
and OHAMINE decrease oxygen consumption with α-
ketoglutaric acid as substrate.
3.6. Anticonvulsant Drugs and Oxygen Consumption In Vivo.
While anticonvulsants had diﬀerent in vitro eﬀects, in vivo all
of them decreased oxygen consumption, but this happened
only when GLU was the substrate (Figure 7(a)). With α
ketoglutaric acid, we found decreases (with PPAL and
HAMINE) as well as increases (AAOA) in oxygen consump-
tion (Figure 7(b)).
4. Discussion
Anticonvulsants aﬀected reductive amination of αK and/or
oxidative deamination of GLU in diﬀerent degree, so the
results of this work show the relevance of considering not
only one but both directions of GDH reaction.
Results analyzing inhibition of oxidative deamination of
GLU induced by PPAL in vitro are in concordance with other
reports [21, 22]. In contrast, decreased reductive amination
of αK caused by AAOA and OHAMINE is in opposition
with other authors, that report no eﬀect of these drugs on
GDH activity using either GLU or αK as substrate [23].
Although some studies indicate GDH isolated from bovine
liver and brain have similar kinetic and allosteric properties
[24,25],kinetic diﬀerenceshave been demonstratedbetween
the liver and brain GDH in the rat [26, 27]. Comparison
of eﬀects on commercially available (bovine liver), liver and
mouse brain GDH activity for both AAOA and OHAMINE,
suggest that the reason of this apparent discrepancy is the
enzyme source. For mouse brain GDH, inhibition of αK
reductive amination in vitro by AAOA and OHAMINE is
competitive with ammonium, which could be explained by
their structure resembling this group in both cases.
Since AAOA increases GABA levels reaching a maxi-
mal at 6 hours, but protection against electroshock and
pentylenetetrazole were maximal 1hr after administration
and had vanished after 6 hours [28], it is considered that
its anticonvulsant action has a dual mechanism. The ﬁrst
one, involving GABA metabolism, most eﬀective 6h after
administration, and the other, not involving GABA, maxi-
mally eﬀective 1.5h after AAOA injection [29], in which is
proposed that GDH may participate regulating GLU levels.
Contrarily to the results observed in vitro, anticonvulsant
in vivo produced a signiﬁcant increase of GLU oxidativeISRN Pharmacology 7
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Figure 7: Eﬀect in vivo of some anticonvulsant drugs on oxy-
gen consumption. Animals received pyridoxal phosphate (PPAL,
50mg/Kg),hydroxylamine(OHAMINE,40mg/kg),andaminooxy-
acetic acid (AAOA, 40mg/Kg). After the treatment, oxygen con-
sumption was determined in brain homogenates (25% wt/vol in
sucrose 0.25M), by a polarographic method using glutamate (a)
and α-ketoglutarate (b) as substrates (see Section 2). Results are
means ± SEM (n>4). ∗Statistically signiﬁcant diﬀerences as
compared with the control (P>0.01, Student’s t test).
deamination, which would lead to a decrease in GLU levels,
hence a diminution of its excitatory eﬀect. The increase and
only slight inhibition in αK reductive amination produced
by OHAMINE and AAOA, respectively, are also opposite to
their eﬀects in vitro.
The diﬀerences between in vitro and in vivo eﬀects of
thesedrugscouldbeattributedtothechangeonbrainenergy
requirements, since GDH activity is highly regulated by
ATP, ADP, GTP, GDP, and other metabolites which indicate
energetic needs. In other words, in vitro results are not under
metabolic regulation as they are in vivo. This hypothesis
seems to be supported by the results obtained analyzing the
eﬀects of anticonvulsants on oxygen consumption, which
indicate diﬀerent metabolic activity, thus diﬀerent energetic
requirements, in vivo as compared with activity in vitro.
Figure 6 shows that, in vitro, anticonvulsant tested
diminished oxygen consumption, but it happened just when
the same substrate in which these drugs decreased GDH
activity was used. On the other hand, in vivo results indicate
that anticonvulsants not only increased oxidative deamina-
tion of GLU but also decreased oxygen consumption with
this substrate. Hence, it could be proposed that changes in
GDH activity have a repercussion on oxygen consumption,
but although in vivo αK is generated by brain GDH, it is not
oxidized in Krebs cycle, maybe because brain metabolism is
decreased and does not require additional energy.
Altogether, our results showed that anticonvulsant eﬀect
of tested substances could involve a decrease in GLU levels by
GDH activation, avoiding its extracellular accumulation and
toxicity. Besides, changes in GDH activity have repercussions
on oxygen consumption, which indicates that the enzyme
activity is highly regulated by energy requirements for
metabolic activity. Then, GDH may participate in neuronal
excitability regulation and may represent a key enzyme in
seizures mechanism.
5. Conclusions
GDH may participate in regulation of GLU and indirectly
GABA levels, hence in neuronal excitability. There is a
relation between oxygen consumption and GDH activity,
which indicate that the enzyme activity is highly regulated by
energy requirements for metabolic activity. Results reinforce
the important role of GDH in GLU metabolism [30],
and suggest that may represent a key enzyme in seizures
mechanism.
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